However, our findings on ADAM17-mediated CD16 reduction in PLWH indicate that techniques in NK cell cancer immunotherapy such as ADAM17 CRISPR knockout and ADAM17-resistant CD16 overexpression could also be translated for use as NK cell-based HIV-1 immunotherapeutics. Here, ADAM17 is linked to cancer.